Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.

Tytuł:: Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.
Autorzy:: Dreyfus I; Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France. .
Maza A; Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.
Rodriguez L; Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.
Merlos M; Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.
Texier H; Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.
Rousseau V; Department of Clinical Pharmacology, CIC1436, University Hospital, Toulouse, France.
Sommet A; Department of Clinical Pharmacology, CIC1436, University Hospital, Toulouse, France.
Mazereeuw-Hautier J; Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.; Paul Sabatier University, Toulouse, France.
Źródło:: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2021 Feb 18; Vol. 16 (1), pp. 93. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [London] : BioMed Central, 2006-
MeSH Terms:: Botulinum Toxins, Type A*/therapeutic use
Darier Disease*
Pemphigus, Benign Familial*/drug therapy
Humans ; Pilot Projects ; Quality of Life
References:: Cutis. 2015 Dec;96(6):E14-6. (PMID: 26761940)
J Dermatolog Treat. 2008;19(5):288-90. (PMID: 18608733)
J Am Acad Dermatol. 2017 Mar;76(3):551-558.e3. (PMID: 27745906)
J Obstet Gynaecol. 2008 Jan;28(1):108-9. (PMID: 18259917)
Dermatol Surg. 2000 Apr;26(4):371-4. (PMID: 10759827)
JAMA Dermatol. 2017 Oct 1;153(10):1018-1020. (PMID: 28768313)
J Invest Dermatol. 2005 Oct;125(4):659-64. (PMID: 16185263)
Br J Plast Surg. 1989 Mar;42(2):230-2. (PMID: 2702374)
Acta Derm Venereol. 2005;85(2):132-5. (PMID: 15823906)
J Dermatol. 2010 Aug;37(8):718-21. (PMID: 20649714)
J Dermatol. 2016 Mar;43(3):275-9. (PMID: 26945535)
Hum Mutat. 2017 Apr;38(4):343-356. (PMID: 28035777)
Br J Dermatol. 2008 Jun;158(6):1393-6. (PMID: 18410420)
Br J Dermatol. 2010 Jan;162(1):227-9. (PMID: 19912213)
Dermatol Surg. 2002 Jun;28(6):543. (PMID: 12081692)
Eur J Dermatol. 2008 Jan-Feb;18(1):87-8. (PMID: 18086602)
J Dermatolog Treat. 2008;19(4):251-4. (PMID: 18629693)
Br J Dermatol. 1996 Dec;135(6):959-63. (PMID: 8977719)
J Cosmet Laser Ther. 2001 Dec;3(4):181-4. (PMID: 12554326)
Dermatol Surg. 1998 Dec;24(12):1411-4. (PMID: 9865214)
Arch Dermatol. 1994 Sep;130(9):1143-9. (PMID: 8085869)
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):370-3. (PMID: 23106313)
Clin Exp Dermatol. 1994 May;19(3):210-6. (PMID: 8033378)
Australas J Dermatol. 2018 Aug;59(3):229-231. (PMID: 29044476)
Pediatr Dermatol. 2011 Mar-Apr;28(2):197-8. (PMID: 20403120)
J Dermatolog Treat. 2017 Nov;28(7):678-682. (PMID: 28301978)
Acta Derm Venereol. 2010 Mar;90(2):179-82. (PMID: 20169303)
Br J Dermatol. 2003 Sep;149(3):606-10. (PMID: 14510996)
Dermatol Surg. 2008 Dec;34(12):1733-7. (PMID: 19076902)
J Eval Clin Pract. 2004 May;10(2):307-12. (PMID: 15189396)
N Engl J Med. 1996 Mar 28;334(13):835-40. (PMID: 8596551)
Br J Dermatol. 2014 Jan;170(1):209-11. (PMID: 23937159)
Qual Life Res. 2015 Apr;24(4):1017-27. (PMID: 25367139)
J Eur Acad Dermatol Venereol. 2006 Jan;20(1):84-7. (PMID: 16405615)
Br J Dermatol. 2018 May;178(5):1196-1198. (PMID: 28991360)
Dermatol Ther. 2010 May-Jun;23(3):302-4. (PMID: 20597949)
JAMA Dermatol. 2018 Jan 1;154(1):106-108. (PMID: 29141083)
JAMA Dermatol. 2017 Oct 1;153(10):1015-1017. (PMID: 28768314)
Clin Exp Dermatol. 2013 Jul;38(5):523-5. (PMID: 23777494)
Ann Dermatol Venereol. 2017 Oct;144(10):599-606. (PMID: 28669425)
Br J Dermatol. 2018 May;178(5):1011-1019. (PMID: 29086923)
Dermatol Surg. 2007 Jul;33(7):882-3. (PMID: 17598861)
Aesthet Surg J. 2017 May 1;37(suppl_1):S4-S11. (PMID: 28388718)
J Cutan Med Surg. 2015 Mar-Apr;19(2):163-6. (PMID: 25775626)
Rev Med Chil. 2011 May;139(5):633-7. (PMID: 22051715)
J Drugs Dermatol. 2015 Jan;14(1):68-70. (PMID: 25607910)
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):51-6. (PMID: 22121995)
Int J Dermatol. 2015 Nov;54(11):1309-14. (PMID: 26341946)
Actas Dermosifiliogr. 2012 Jul-Aug;103(6):532-5. (PMID: 21872830)
An Bras Dermatol. 2010 Sep-Oct;85(5):717-22. (PMID: 21152802)
J Drugs Dermatol. 2011 Sep;10(9):1013-5. (PMID: 22052270)
N Engl J Med. 2001 Feb 15;344(7):488-93. (PMID: 11172190)
Grant Information:: 14 7316 02 Institutional Funder of Toulouse hospital named "Appel d'Offre Local" (2014)
Contributed Indexing:: Keywords: Botulinum toxin; Darier disease; Hailey hailey disease; Quality of life
Substance Nomenclature:: EC 3.4.24.69 (Botulinum Toxins, Type A)
Entry Date(s):: Date Created: 20210219 Date Completed: 20210618 Latest Revision: 20230320
Update Code:: 20240105
PubMed Central ID:: PMC7893874
DOI:: 10.1186/s13023-021-01710-x
PMID:: 33602313
: Czasopismo naukowe

Pełny tekst

Background: Patients with Hailey-Hailey and Darier diseases present with disabling inflammatory lesions located in large skin folds, which are often exacerbated or induced by sweating. Quality of life is highly impaired because of pain and recurrent skin infections. An improvement in skin lesions after botulinum toxin A injections has previously been reported in some patients but no prospective interventional studies are available. The aim of this open-label, 6-month, interventional pilot study (NCT02782702) was to evaluate the effectiveness and safety of botulinum toxin A for patients with moderate to very severe skin lesions located in folds.
Results: Thirty patients (26 Hailey-Hailey/4 Darier) were included. Botulinum toxin A proved effective within the first month in two-thirds of patients, taking all study parameters (itchiness, cutaneous pain, sweating and odour, infections, psychosocial impairment and quality of life) into account and persisted during the 6-month follow-up period. No patient was classed as a BtxA non-responder, but 11 (37%) Hailey-Hailey patients (the most severe ones), experienced a relapse during the study. No serious side effects were reported. Mild transient clear fluid discharge at the site of the injections was reported for 27% of patients.
Conclusions: Botulinic toxin seems to be an effective and safe treatment for Hailey-Hailey and Darier diseases. Nevertheless, it may prove insufficient for the severest of Hailey-Hailey cases and could be considered as supplementary to other conventional treatments. Further studies are required to confirm our results on larger Darier cohorts.

Comment in: Dermatol Ther. 2022 Dec;35(12):e15841. (PMID: 36124888)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja